"It's the human decay that troubles me the most," says photographer Seph Lawless.
Lawless' new book, "Black Friday" displays his photographs of malls in the Rust Belt states of Ohio and Michigan.
He calls his project an "autopsy of America."
"The most bizarre was seeing gun shots all over one mall," he said, remembering his visit to Rolling Acres Mall in Ohio. "Shattered glass sky lights and store fronts."
Retail analysts can't say how many malls have failed. But they do know that only two new malls have been built in the past eight years.
"That tells you where the malls are going: nowhere," said Howard Davidowitz, chairman of retail consulting and investment banking firm Davidowitz & Associates, Inc. He believes that half the nation's 1,500 malls will fail in the next 20 years.
Top 5 Asian Stocks To Watch For 2015: Northland Power Inc (NPIFF.PK)
Northland Power Inc. (Northland) owns or has an economic interests, through its subsidiaries, in operating power-producing facilities and a pipeline of construction and development projects. Its operating assets consist of facilities, which produce electricity from natural gas and renewable sources. Its subsidiaries include Iroquois Falls Corp., which owns the Iroquois Falls Facility; Kingston LP, which owns the Kingston Facility; Thorold LP, which owns the Thorold Facility; Mont Miller LP; Jardin LP, which owns the Jardin wind farm; DK Windpark Kavelstorf GmbH & Co. KG and DK Burgerwindpark Eckolstadt GmbH & Co. KG, which own the German Wind Farms; Mont Louis LP, which owns the Mont Louis Wind Farm; Spy Hill LP, which owns the Spy Hill Facility, and North Battleford LP, which owns the North Battleford Facility. Northland owns a 19% interest in Panda Energy Corporation, which through its wholly owned subsidiaries owns the 230 mega-watts combined-cycle Panda-Brandywine facility. Advisors' Opinion:- [By Markus Aarnio]
Emera's competitors include Northland Power (NPIFF.PK), Fortis (FRTSF.PK), and Atlantic Power (AT). Northland Power has seen insider buying in August and has a dividend yield of 7.6%. Fortis has seen both insider buying and insider selling in August. Fortis has a dividend yield of 4.1%. Atlantic Power saw insider buying last time in April. Atlantic Power has a dividend yield of 9.4%.
Best Healthcare Technology Companies To Own In Right Now: Xoom Corp (XOOM)
Xoom Corporation (Xoom), incorporated on October 10, 2012, is engaged in online international money transfer service. Its customers use Xoom to send money to family and friends in 30 countries. The Company generates revenue from transaction fees charged to customers and from foreign exchange spreads on transactions where the payout currency is other than United States dollars. In February 2014, Xoom Corp acquired BlueKite, LTD, a technology company that develops solutions and applications.
The Company�� solutions are designed to offer customers a convenient, fast and cost-effective way to send money to family and friends at any time, from any Internet-enabled location. The Company�� solutions include Origination, Funding, Disbursement and Transaction Processing.
Advisors' Opinion:- [By John Kell]
Xoom Corp.(XOOM) swung to a fourth-quarter profit as the international money-transfer provider reported a jump in revenue. But the company’s full-year earnings outlook fell short of Wall Street’s expectations. Shares dropped 13% to $24.46 premarket.
- [By Jake L'Ecuyer]
Equities Trading UP
Xoom (NASDAQ: XOOM) shares shot up 15.58 percent to $22.77 after the company reported upbeat Q1 results and issued a strong FY14 outlook.
Best Healthcare Technology Companies To Own In Right Now: Fonar Corporation(FONR)
FONAR Corporation engages in the research, development, production, marketing, and service of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases. It provides Upright Multi-positional MRI scanners, which allow patients to be scanned in a weight-bearing condition, such as standing, sitting, or bending in any position that causes symptoms; and FONAR 360 MRI scanner, a diagnostic scanner. The company, through its wholly owned subsidiary, Health Management Corporation of America, also offers management services to imaging facilities, including development, administration, and leasing of office space, facilities, and medical equipment; provision of supplies; staffing, training, and supervision of non-medical personnel; legal services; accounting, billing, and collection; and the development and implementation of practice growth and marketing strategies. It serves private diagnostic imaging centers and hospitals. As of June 30, 2011, the c ompany managed 10 diagnostic imaging facilities located in the states of New York and Florida. FONAR Corporation was founded in 1978 and is based in Melville, New York.
Advisors' Opinion:- [By Monica Gerson]
Breaking news
NASDAQ OMX Group (Nasdaq: NDAQ) and Borsa Istanbul A.S. have today concluded a wide-ranging agreement, which includes the delivery of market-leading technologies and advisory services to Borsa Istanbul, and NASDAQ OMX taking an equity stake in Borsa Istanbul. To read the full news, click here. Acacia Research (NASDAQ: ACTG) announced today that its Bolt MRI Technologies LLC subsidiary has entered into an agreement with Fonar Corporation (NASDAQ: FONR). To read the full news, click here. Douglas Emmett, (NYSE: DEI) announced that William Kamer will be retiring from full time service as its Chief Investment Officer effective January 31, 2014. Mr. Kamer will continue to be employed by Douglas Emmett as a Senior Advisor. To read the full news, click here. Acacia Research (NASDAQ: ACTG) announced today that its Brandywine Communications Technologies LLC subsidiary has entered into a settlement and patent license agreement with Alcatel-Lucent USA (NYSE: ALU). To read the full news, click here.Posted-In: Benchmark US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets
Best Healthcare Technology Companies To Own In Right Now: Ambit Biosciences Corp (AMBI)
Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Quizartinib
The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.
AC410
The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.
CSF1R Program
The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.
The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.
Advisors' Opinion:- [By Wallace Witkowski]
Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.
Best Healthcare Technology Companies To Own In Right Now: TherapeuticsMD Inc (TXMD)
TherapeuticsMD, Inc., incorporated in 1907, promotes, distributes and sells certain products developed and sold by Spectrum Health Network, Inc. (Spectrum) relative to its digital media network. Through the license agreement, the Company focuses on multispecialty group practices and independent physician associations (IPAs) to sell them subscriptions for software, hardware and content developed for and distributed by Spectrum. Spectrum sells its network to IPAs for equipment and installation. On October 4, 2011, the Company acquired VitaMedMD, LLC (VitaMedMD). As a result of the acquisition, VitaMedMD became a wholly owned subsidiary of the Company.
VitaMedMD is a specialty pharmaceutical company, VitaMed is focused on providing products to the women�� health market. The Company focuses on market both over-the-counter (OTC) and prescription nutritional supplements, drugs, medical foods and other medical products through pharmacies and its Web-site. Its brand includes a range of products for women�� health and associated with pregnancy, child birth, nursing, post birth and menopause. Its OTC product line available through its Website includes prenatal vitamins, DHA, iron supplements, calcium supplements, Vitamin D supplements, women�� multivitamins, natural (non-hormonal) menopause relief, and scar reduction creams. In March 2012, the Company launched its first prescription-only prenatal vitamin, vitaMedMD Plus Rx.
vitaMedMD Plus Prenatal Multi-Vitamin + DHA is a two pill combo pack that contains 18 essential vitamins and minerals and 300 milligrams (mg) of life�� DHA. vitaMedMD is a single dose daily multivitamin that provides 14 vitamins, minerals and 200 mg of vegetarian, plant-pure life�� DHA. vitaMedMD Plus Rx is a product with a single-dose combo-pack containing one prenatal vitamin tablet with Quatrefolic Acid. vitaMedMD Plus Rx is a product with a single-dose daily multivitamin containing Quatrefolic Acid. vitaMedMD Iron-150 is a iron replacement supplement. ! vitaMedMD Menopause Relief with Lifenol Plus Bone Support offers a natural solution for hot flashes, night sweats and mood disturbances. vitaMedMD Calcium + Vitamin D is a dietary supplements that help replenish and maintain beneficial levels of Vitamin D. vitaMedMD Stretch Mark Body Cream contains naturally-derived ingredients, including Peptides, Shea Butter, Sweet Almond Oil and Fruit Extracts, that hydrate, soothe and pamper skin to make it softer, smoother and younger-looking.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 specialty pharmaceutical player that's starting to trend within range of triggering a big breakout trade is TherapeuticsMD (TXMD), which is focused on the sales, marketing and development of branded and generic pharmaceutical and OTC products primarily for the women's health care market. This stock has been in play with the bulls so far in 2013, with shares up 56%.
If you take a look at the chart for TherapeuticsMD, you'll notice that this stock has been uptrending strong over the last three months, with shares soaring higher from its low of $2.03 to its recent high of $5.27 a share. During that uptrend, shares of TXMD have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of TXMD within range of triggering a big breakout trade.
Traders should now look for long-biased trades in TXMD if it manages to break out above some near-term overhead resistance levels at $4.93 a share to its 52-week high at $5.27 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 450,661 shares. If that breakout triggers soon, then TXMD will set up to enter new 52-week high territory, which is bullish technical price action. Some possible upside targets off that breakout are $6 to $7 a share.
Traders can look to buy TXMD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at 4.30 a share, or near its 50-day moving average of $4.15 a share. One can also buy TXMD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By John Udovich]
Yesterday, mid cap women�� health stock Hologic, Inc (NASDAQ: HOLX) fell more than 10% after disappointing Wall Street on earnings,�meaning it might be time to take a look at it and�small cap women�� health stocks�The Female Health Company (NASDAQ: FHCO) and TherapeuticsMD Inc (NYSEMKT: TXMD) because after all, women account for half the population and these three small caps are all focused on the women�� health:
Best Healthcare Technology Companies To Own In Right Now: tw telecom inc.(TWTC)
tw telecom inc. engages in the provision of managed network services in the United States. The company offers data networking, converged, Internet protocol based virtual private network (IP VPN), and Internet access services. The company?s data services include switched native local area network (NLAN), point-to-point elite NLAN, E-Line, extended NLAN, regional ethernet, and IP VPN and managed IP VPN services; and converged and integrated services. It also provides high capacity Internet service with bandwidth speeds ranging from 1.5 Mbps to 10 Gbps to access the Internet and other external networks; and managed services comprising enhanced management services, managed security services, collocation services, and distributed denial of service mitigation. In addition, the company offers network access services for voice, data, image, and video transmission, such as private line, special access, transport arrangements, and metropolitan and regional connectivity; and voice s ervices that provide customers with local and long distance calling capabilities consisting of access trunk, long distance, local toll, local telephone, business access line, and IP trunk services. Further, it offers intercarrier services, such as switched access and local traffic termination services. As of December 31, 2011, the company?s fiber network spanned approximately 27,000 route miles connecting to 15,438 buildings. Its customers include enterprise organizations in the distribution, health care, finance, service, and manufacturing industries; state, local, and federal government entities; system integrators; and communication service providers, such as incumbent local exchange carriers, competitive local exchange carriers, wireless communications, and cable companies. The company was formerly known as Time Warner Telecom Inc. and changed its name to tw telecom inc. in March 2008. tw telecom inc. was founded in 1993 and is headquartered in Littleton, Colorado.
Advisors' Opinion:- [By Jesse Solomon]
The latest deals include medical device maker Medtronic's (MDT) $42.9 billion acquisition of rival Coviden (COV), telecom giant Level 3 Communications' (LVLT) $5.7 billion purchase of tw telecom (TWTC), Williams Companies (WMB)' $6 billion controlling stake in natural gas driller Access Midstream Partners (ACMP), and SanDisk's (SNDK) $1.1 billion takeover of flash technology company Fusion-io (FIO).
- [By Garrett Cook]
TW Telecom (NASDAQ: TWTC) jumped 8.5 percent to $38.43 after the company agreed to be acquired by Level 3 Communications (NYSE: LVLT) in a stock-and-cash transaction valued at $40.86 per share.
- [By Garrett Cook]
TW Telecom (NASDAQ: TWTC) jumped 7.04% to $38.90 after the company agreed to be acquired by Level 3 Communications (NYSE: LVLT) in a stock-and-cash transaction valued at $40.86 per share.
No comments:
Post a Comment